The BioMed X Institute
6.6.2024 14:57:41 CEST | ACCESS Newswire | Press release
A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
RIDGEFIELD, CT / ACCESSWIRE / June 5, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.
The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."
"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.
"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.
About BioMed X and XSeed Labs
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
Related Images
SOURCE: BioMed X Institute & XSeed Labs
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Driving the World's Leading Supply Chains: 9 OMP Customers Named to The 2026 Gartner Top 2518.6.2026 15:00:00 CEST | Press release
As global leaders move from firefighting to foresight, OMP celebrates the enterprise visionaries scaling decision-driven intelligence at the speed of change. ANTWERPEN, BE / ACCESS Newswire / June 18, 2026 / OMP, a leading AI-powered provider of supply chain planning solutions, extends its congratulations to the 9 customer organizations recognized in the newly released Gartner® Supply Chain Top 25 and Masters for 2026. Now in its 22nd year, the Gartner Supply Chain Top 25 remains the definitive benchmark for supply chain excellence, evaluating global enterprises on financial performance, ESG initiatives, and community opinion. This year's rankings point to three capabilities separating market leaders: building an autonomous workforce where people and intelligent systems collaborate on decisions, adopting network-centric strategies that treat supply chain design as a continuous, adaptive process, and orchestrating decisions end-to-end across increasingly complex ecosystems. OMP's custom
U.S. Polo Assn. Unveils Spring-Summer 2027 Collection at the 110th Edition of Pitti Immagine Uomo18.6.2026 13:00:00 CEST | Press release
Global Sports Brand Puts the Iconic Polo Shirt at the Center of its Pitti Uomo Experience FLORENCE, IT AND WEST PALM BEACH, FL / ACCESS Newswire / June 18, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned to Florence, Italy, for Pitti Immagine Uomo 110 to present The Polo Shirt: An Icon Born from the Game™ and its Spring-Summer 2027 Global Collection showcasing a modern, global expression of the sport-inspired lifestyle. The collection includes classic, sport-inspired apparel, footwear, bags, and accessories that blend authentic American-inspired sports style with European craftsmanship. 1) Polo Shirt Installation for U.S. Polo Assn. Booth at Pitti Uomo 110 in Florence, Italy 2) U.S. Polo Assn. Booth at Pitti Uomo 110 featuring The Polo Shirt: An Icon Born from the Game 3) Pitti Uomo 110 Attendees Crowd the U.S. Polo Assn. Booth U.S. Polo Assn.'s exhibit at Pitti Uomo is taking place from June 16 to 19, 2026, at Booth 32 Cavanigli
Deadline Extended for 2026 Semmelweis-Richter Journalism Award Applications18.6.2026 11:30:00 CEST | Press release
Following strong interest and numerous requests, the application deadline for the 2026 Semmelweis-Richter Journalism Award has been extended by two weeks. Submissions are now accepted until June 23, 2026, 23:59 CET. BUDAPEST, HU / ACCESS Newswire / June 18, 2026 / Building on the success of its inaugural edition, the award continues to recognise outstanding journalism that contributes to public understanding of key health issues and fosters informed discussion across Europe. The initiative is organised by Semmelweis University, Hungary's leading medical and health sciences institution, in partnership with Gedeon Richter, a Hungary-based, innovation-driven specialty pharmaceutical company. Entries are invited in two categories: Women's Health and Pharmaceutical Strategies and Innovation, the latter placing particular emphasis on cardiovascular therapies. The organisers welcome high-quality reporting that sheds light on pressing or underrepresented health topics, addresses stigma, and su
LiberNovo Announces Early Launch of Prime Sale, Featuring Limited Omni Bundle Flash Deals Starting Today18.6.2026 04:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 17, 2026 / LiberNovo today opened early access to its 2026 Prime Sale, with up to 49% off and a limited run of flash-deal bundles built around the original LiberNovo Omni. Early access is live now, and the full sale runs June 23 through July 11. LiberNovo makes dynamic ergonomic chairs, the first designed to respond to your body as it moves. Instead of locking you into one fixed posture, the dynamic support system keeps the neck support, backrest, armrests, and seat moving together as you shift, lean, and recline. Prime Sale - Omni Series Clearance Deals The original LiberNovo Omni is available at Prime Sale clearance pricing while stocks last, with prices starting as low as €939 (49% off in the EU) and £869 (46% off in the UK), representing significant savings for consumers. The original LiberNovo Omni - the first dynamic ergonomic chair - features an eight-panel Bionic FlexFit Backrest and automatic armrests that move with you through every shif
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA18.6.2026 00:10:00 CEST | Press release
Company Will Produce Service's New Uncrewed Combat Jets SAN DIEGO, CA / ACCESS Newswire / June 17, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has received a production contract from the U.S. Air Force (USAF) for the FQ-42A Collaborative Combat Aircraft (CCA). The initial order is a significant milestone, beginning the delivery of production aircraft to the warfighter. GA-ASI designed, developed and flight-tested FQ-42A on an accelerated schedule unlike any fighter in recent history. "This is an exciting day for our company and the nation," said company President David R. Alexander. "Moving to production on FQ-42A is the result of an extraordinary partnership and many years of investments between General Atomics and the U.S. Air Force. We've been preparing for this order, and manufacturing is already well underway." The FQ-42A is a purpose-built, uncrewed fighter developed as part of ongoing investment in next-generation semi-autonomous combat aircraft. The aircraft's mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom